Xortx Therapeutics Inc (XRTX) Stock Price, Quote & News

Company Profile

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus;...

Industry: Biotechnology

Sector: Healthcare

Phone: 403-455-7727

Website: www.xortx.com

Address:

3710 - 33rd Street NW, Calgary, Canada

RoyalImperial Apr. 25 at 5:33 PM

MITQ ✅ Has that look for next week, one of the most undervalued and cleanest micro caps. Latest news + contracts rolling in Low float (6M) NO dilution Record earnings trend 📈. A $9M projector refresh contract plus other large projects shifting into FY2026 means a significant revenue surge is likely already locked in and coming. $ZEO $PLRZ $TZOO $XRTX watching ..

0 · Reply

Royal_Imperial Apr. 24 at 9:46 PM

MITQ looking ready, keep eyes on this one. Latest news + contracts rolling in Low float (~sub 10M) NO dilution Record earnings trend 📈. MITQ super undervalued-The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $SMX $VFS $BIYA $XRTX ww//.55

0 · Reply

LookaLike Apr. 24 at 4:39 PM

$XRTX yes picking up

0 · Reply

honestrick Apr. 24 at 2:38 PM

$XRTX They may need $$$$ but with the pipe line they have and the 3 new directors who ALL have connections to investors $$$ should hold the price .It will bounce around but should start to climb . $DRUG

0 · Reply

honestrick Apr. 24 at 2:28 PM

$XRTX

0 · Reply

Reminderz Apr. 23 at 8:07 PM

$XRTX $WNW $SKK $LNKS smart

0 · Reply

LookaLike Apr. 23 at 6:27 PM

$XRTX the presplit price is 0,54, this is still very low. This should trade at least at 10 Million marketcap with the acquisition they finalized. This would translate into 7 $ per share considering 1.5 million shares outstanding

0 · Reply

LookaLike Apr. 22 at 7:03 PM

$XRTX from red to green, nice performance

0 · Reply

TheBeautifulGopher Apr. 22 at 1:01 PM

$XRTX hello XRTX board, you had a nice pop for compliance news. $HKIT did their reverse split the same time as you and we’re waiting for ours. Should be getting it tomorrow 😎

0 · Reply

Goldwave9 Apr. 22 at 12:39 PM

$XRTX Another sleeper that's playing dead...for now

0 · Reply

XORTX Confirms Effective Date of Share Consolidation

Thu, 26 Mar 2026 18:00:00 -0400 - 4 weeks ago

XORTX Announces Results of Annual and Special Meeting of Shareholders

Thu, 26 Mar 2026 16:32:00 -0400 - 4 weeks ago

XORTX Announces Change of Effective Date of Share Consolidation

Wed, 25 Mar 2026 18:15:00 -0400 - 4 weeks ago

XORTX Announces Share Consolidation

Fri, 13 Mar 2026 07:00:00 -0400 - 6 weeks ago

XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation

2026-03-05T12:33:09.000Z - 7 weeks ago

XORTX Therapeutics (XRTX) Announces Key Shareholder Meeting Agenda

2026-02-05T09:34:03.000Z - 2 months ago

Why Align Technology Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

2026-02-05T07:10:06.000Z - 2 months ago

XORTX Extends Closing Of Renal Anti-Fibrotic Therapeutic Program Acquisition; Stock Soars

Tue, 21 Oct 2025 08:00:00 -0400 - 6 months ago

XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

2025-10-21T06:55:29.000Z - 6 months ago

XORTX Therapeutics (XRTX) Secures Nasdaq Extension to Meet Bid Price Rule

Mon, 20 Oct 2025 20:34:00 -0400 - 6 months ago

XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

Mon, 20 Oct 2025 18:45:00 -0400 - 6 months ago

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

2025-10-17T12:35:39.000Z - 6 months ago

XORTX (XRTX) Acquires Renal Therapeutic Program from Vectus

Fri, 17 Oct 2025 07:00:00 -0400 - 6 months ago

XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

2025-09-09T13:01:00.000Z - 8 months ago

XORTX Therapeutics goes ‘toe to toe’ with gout by accelerating its lead drug program targeting this complex disease

Wed, 03 Sep 2025 07:00:00 -0400 - 8 months ago

XORTX Initiates IND Preparation for XORLO™ in Gout Program

Fri, 08 Aug 2025 19:54:00 -0400 - 9 months ago

XORTX Completes USD $114,500 Private Placement

Tue, 22 Jul 2025 19:59:00 -0400 - 9 months ago

XORTX Completes Non-Brokered Private Placement of Units

Thu, 26 Jun 2025 07:00:00 -0400 - 10 months ago

XORTX Announces USD $925,000 Private Placement

Mon, 19 May 2025 07:00:00 -0400 - 1 year ago

XORTX Announces USD $3 Million Offering

2025-04-18T07:55:25.000Z - 1 year ago

XORTX Therapeutics (XRTX) Faces Nasdaq Compliance Challenge

Thu, 17 Apr 2025 19:45:00 -0400 - 1 year ago

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

2025-02-15T11:02:46.000Z - 1 year ago

ARMISTICE CAPITAL, LLC Acquires Shares in XORTX Therapeutics Inc

Fri, 17 Jan 2025 17:00:00 -0500 - 1 year ago

XORTX Announces Change of Auditor

2024-12-13T07:01:58.000Z - 1 year ago

IRW-News: XORTX Therapeutics Inc.: XORTX kündigt Präsentation auf dem Rare and Genetic Disease Summit an

Thu, 12 Dec 2024 09:17:00 -0500 - 1 year ago

XORTX Announces Presentation at the Rare and Genetic Disease Summit

Fri, 18 Oct 2024 16:00:00 -0400 - 1 year ago

XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

Wed, 09 Oct 2024 05:00:00 -0400 - 1 year ago

XORTX Initiates Precision Medicine Program

Fri, 13 Sep 2024 07:00:00 -0400 - 1 year ago

XORTX Announces Results of Annual and Special Meeting of Shareholders

Thu, 12 Sep 2024 17:30:00 -0400 - 1 year ago

XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A

Fri, 06 Sep 2024 17:30:00 -0400 - 1 year ago

XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders

Tue, 03 Sep 2024 12:30:00 -0400 - 1 year ago

Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

Fri, 23 Aug 2024 07:00:00 -0400 - 1 year ago

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

Tue, 20 Aug 2024 07:00:00 -0400 - 1 year ago

XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024

Fri, 17 May 2024 07:00:00 -0400 - 2 years ago

XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO

Tue, 30 Apr 2024 13:54:00 -0400 - 2 years ago

XORTX Reprices Warrants Issued in Connection with Previous Private Placements

Mon, 22 Apr 2024 07:00:00 -0400 - 2 years ago

XORTX Announces Publication of Key Research in ADPKD

Mon, 08 Apr 2024 07:30:00 -0400 - 2 years ago

XORTX Welcomes New Member to the Board of Directors

Wed, 27 Mar 2024 05:00:00 -0400 - 2 years ago

XORTX Announces New Clinical Advisory Board Member

Tue, 19 Mar 2024 05:00:00 -0400 - 2 years ago

XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial

Mon, 04 Mar 2024 07:00:00 -0500 - 2 years ago

XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units

Thu, 01 Feb 2024 20:46:00 -0500 - 2 years ago

XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units

Mon, 15 Jan 2024 07:00:00 -0500 - 2 years ago

XORTX Announces $2 Million Public Offering

Wed, 03 Jan 2024 07:00:00 -0500 - 2 years ago

XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease

Thu, 30 Nov 2023 07:30:00 -0500 - 2 years ago

XORTX Announces US ATM Offering

Wed, 29 Nov 2023 07:00:00 -0500 - 2 years ago

XORTX Meets Nasdaq Continued Listing Requirements

Fri, 10 Nov 2023 07:00:00 -0500 - 2 years ago

XORTX Clarifies Timing for Share Consolidation

Wed, 08 Nov 2023 17:00:00 -0500 - 2 years ago

XORTX Announces Share Consolidation

Fri, 27 Oct 2023 17:30:00 -0400 - 2 years ago

XORTX Announces Results of Special Meeting of Shareholders

Oct 25, 2023, 5:00 PM EDT - 2 years ago

XORTX Announces Date for Rescheduled Special Meeting of Shareholders

Oct 25, 2023, 7:00 AM EDT - 2 years ago

XORTX Announces Rescheduling of Special Meeting of Shareholders

Oct 12, 2023, 7:00 AM EDT - 2 years ago

XORTX Reports that Independent Proxy Firm, ISS, Recommends Shareholders Vote for the Share Consolidation Resolution

Oct 4, 2023, 7:00 AM EDT - 2 years ago

XORTX Calls Special Meeting of Shareholders

Aug 29, 2023, 7:00 AM EDT - 2 years ago

XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease

Aug 4, 2023, 5:00 PM EDT - 2 years ago

XORTX Appoints Chief Financial Officer

Jun 23, 2023, 8:51 PM EDT - 3 years ago

XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company's Upcoming Annual and Special Meeting of Shareholders

May 24, 2023, 7:00 AM EDT - 3 years ago

XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

Apr 21, 2023, 7:00 AM EDT - 3 years ago

XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Kidney Disease

Feb 1, 2023, 7:00 AM EST - 3 years ago

XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease

Jan 19, 2023, 7:00 AM EST - 3 years ago

XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial

RoyalImperial Apr. 25 at 5:33 PM

0 · Reply

Royal_Imperial Apr. 24 at 9:46 PM

0 · Reply

LookaLike Apr. 24 at 4:39 PM

$XRTX yes picking up

0 · Reply

honestrick Apr. 24 at 2:38 PM

0 · Reply

honestrick Apr. 24 at 2:28 PM

$XRTX

0 · Reply

Reminderz Apr. 23 at 8:07 PM

$XRTX $WNW $SKK $LNKS smart

0 · Reply

LookaLike Apr. 23 at 6:27 PM

0 · Reply

LookaLike Apr. 22 at 7:03 PM

$XRTX from red to green, nice performance

0 · Reply

TheBeautifulGopher Apr. 22 at 1:01 PM

$XRTX hello XRTX board, you had a nice pop for compliance news. $HKIT did their reverse split the same time as you and we’re waiting for ours. Should be getting it tomorrow 😎

0 · Reply

Goldwave9 Apr. 22 at 12:39 PM

$XRTX Another sleeper that's playing dead...for now

0 · Reply

Mr_Stochastic Apr. 22 at 11:17 AM

$XRTX $BATL $FFAI $SOXL

0 · Reply

DavidScott Apr. 22 at 4:22 AM

On watch tomorrow (momentum) // Part 1 🔥📈📚 $BYND $LOBO $FCHL $RPGL $XRTX

0 · Reply

DayTrade_4Life Apr. 22 at 12:21 AM

💵From the Watchlist and Alerts Today 21 April 26: 💪See image for Top Alerts this month. $SPRC: 5.33 to 8.42 (57%) $LOBO: .91 to 1.35 (48%) $RPGL: .65 to .92 (41%) $EDBL: 1.28 to 1.65 (28%) $XRTX: 2.94 to 3.73 (26%) TDIC: 1 to 1.20 (20%) VELO: 14 to 16.10 (13%)

0 · Reply

Longislandbull Apr. 22 at 12:10 AM

We banked HARD today in so many different names! One of our co founders made $202K on the day! Come trade with us for a free week trial below 👇 https://trifectatrading.tiiny.site/ $NAIL $LOBO $LWLG $XRTX $IGV

0 · Reply

Oooox Apr. 22 at 12:00 AM

$XRTX 🚀📍

0 · Reply

Mr_Stochastic Apr. 21 at 10:04 PM

$XRTX $BATL $FFAI $SOXL Testing out $BANL for an overnight hold. 💪🏼😎💰

0 · Reply

BreakoutBullz Apr. 21 at 9:32 PM

🛎️🤑 Trade Recap 🤑🛎️ $LOBO ran 🔥💰🎯 +42% from .95 call! $XRTX ran 🔥💰🎯 +33% from 2.80 call! $EDBL 🔥💰🎯 +32% from 1.25 call! $FFAI ran 🔥💰🎯 +24% from .48 call! $TDIC 🔥💰🎯 +20% from .90 call!

0 · Reply

Mr_Stochastic Apr. 21 at 8:31 PM

$XRTX $BATL $FFAI $SOXL tomorrow we ride again! Until then....

0 · Reply

Mr_Stochastic Apr. 21 at 8:06 PM

$XRTX $BATL $FFAI $SOXL hope you banked with me today. Banger after banger!!! Follow. Subscribe. Bank. 💪🏼😎💰

1 · Reply

Reda1235 Apr. 21 at 7:30 PM

$XRTX

0 · Reply

Maryam2000 Apr. 21 at 5:21 PM

$XRTX

0 · Reply

UTrades Apr. 21 at 4:34 PM

$NVTS, $XRTX, $LOCL Good day trading stocks with decent volume and good volatility. All sitting below VWAP right now.

0 · Reply

Market Cap	3.86M
Revenue (ttm)	0.00
Net Income (ttm)	-2.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	472,300
Avg Vol	1,537,890
Day's Range	N/A - N/A
Shares Out	1.39M
Stochastic %K	64%
Beta	0.46
Analysts	Strong Buy
Price Target	$70.00